<?xml version='1.0' encoding='utf-8'?>
<document id="27041642"><sentence text="Cobicistat Significantly Increases Tacrolimus Serum Concentrations in a Renal Transplant Recipient with Human Immunodeficiency Virus Infection." /><sentence text="Cobicistat is a pharmacokinetic booster in several fixed-dose combination products for treatment of human immunodeficiency virus (HIV) infection" /><sentence text=" As a potent inhibitor of cytochrome P450 (CYP) 3A enzymes, significant drug-drug interactions are expected between cobicistat and medications that are metabolized primarily through the CYP3A pathway, including calcineurin inhibitors (e" /><sentence text="g" /><sentence text=", tacrolimus and cyclosporine)"><entity charOffset="2-12" id="DDI-PubMed.27041642.s5.e0" text="tacrolimus" /><entity charOffset="17-29" id="DDI-PubMed.27041642.s5.e1" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.27041642.s5.e0" e2="DDI-PubMed.27041642.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27041642.s5.e0" e2="DDI-PubMed.27041642.s5.e1" /></sentence><sentence text=" We describe a case of tacrolimus toxicity due to supratherapeutic tacrolimus concentrations when Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) was initiated for newly diagnosed HIV infection in a 50-year-old renal transplant recipient who was previously receiving a stable tacrolimus regimen"><entity charOffset="23-33" id="DDI-PubMed.27041642.s6.e0" text="tacrolimus" /><entity charOffset="67-77" id="DDI-PubMed.27041642.s6.e1" text="tacrolimus" /><entity charOffset="108-120" id="DDI-PubMed.27041642.s6.e2" text="elvitegravir" /><entity charOffset="122-132" id="DDI-PubMed.27041642.s6.e3" text="cobicistat" /><entity charOffset="134-147" id="DDI-PubMed.27041642.s6.e4" text="emtricitabine" /><entity charOffset="153-182" id="DDI-PubMed.27041642.s6.e5" text="tenofovir disoproxil fumarate" /><entity charOffset="314-324" id="DDI-PubMed.27041642.s6.e6" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.27041642.s6.e0" e2="DDI-PubMed.27041642.s6.e0" /><pair ddi="false" e1="DDI-PubMed.27041642.s6.e0" e2="DDI-PubMed.27041642.s6.e1" /><pair ddi="false" e1="DDI-PubMed.27041642.s6.e0" e2="DDI-PubMed.27041642.s6.e2" /><pair ddi="false" e1="DDI-PubMed.27041642.s6.e0" e2="DDI-PubMed.27041642.s6.e3" /><pair ddi="false" e1="DDI-PubMed.27041642.s6.e0" e2="DDI-PubMed.27041642.s6.e4" /><pair ddi="false" e1="DDI-PubMed.27041642.s6.e0" e2="DDI-PubMed.27041642.s6.e5" /><pair ddi="false" e1="DDI-PubMed.27041642.s6.e0" e2="DDI-PubMed.27041642.s6.e6" /><pair ddi="false" e1="DDI-PubMed.27041642.s6.e1" e2="DDI-PubMed.27041642.s6.e1" /><pair ddi="false" e1="DDI-PubMed.27041642.s6.e1" e2="DDI-PubMed.27041642.s6.e2" /><pair ddi="false" e1="DDI-PubMed.27041642.s6.e1" e2="DDI-PubMed.27041642.s6.e3" /><pair ddi="false" e1="DDI-PubMed.27041642.s6.e1" e2="DDI-PubMed.27041642.s6.e4" /><pair ddi="false" e1="DDI-PubMed.27041642.s6.e1" e2="DDI-PubMed.27041642.s6.e5" /><pair ddi="false" e1="DDI-PubMed.27041642.s6.e1" e2="DDI-PubMed.27041642.s6.e6" /><pair ddi="false" e1="DDI-PubMed.27041642.s6.e2" e2="DDI-PubMed.27041642.s6.e2" /><pair ddi="false" e1="DDI-PubMed.27041642.s6.e2" e2="DDI-PubMed.27041642.s6.e3" /><pair ddi="false" e1="DDI-PubMed.27041642.s6.e2" e2="DDI-PubMed.27041642.s6.e4" /><pair ddi="false" e1="DDI-PubMed.27041642.s6.e2" e2="DDI-PubMed.27041642.s6.e5" /><pair ddi="false" e1="DDI-PubMed.27041642.s6.e2" e2="DDI-PubMed.27041642.s6.e6" /><pair ddi="false" e1="DDI-PubMed.27041642.s6.e3" e2="DDI-PubMed.27041642.s6.e3" /><pair ddi="false" e1="DDI-PubMed.27041642.s6.e3" e2="DDI-PubMed.27041642.s6.e4" /><pair ddi="false" e1="DDI-PubMed.27041642.s6.e3" e2="DDI-PubMed.27041642.s6.e5" /><pair ddi="false" e1="DDI-PubMed.27041642.s6.e3" e2="DDI-PubMed.27041642.s6.e6" /><pair ddi="false" e1="DDI-PubMed.27041642.s6.e4" e2="DDI-PubMed.27041642.s6.e4" /><pair ddi="false" e1="DDI-PubMed.27041642.s6.e4" e2="DDI-PubMed.27041642.s6.e5" /><pair ddi="false" e1="DDI-PubMed.27041642.s6.e4" e2="DDI-PubMed.27041642.s6.e6" /><pair ddi="false" e1="DDI-PubMed.27041642.s6.e5" e2="DDI-PubMed.27041642.s6.e5" /><pair ddi="false" e1="DDI-PubMed.27041642.s6.e5" e2="DDI-PubMed.27041642.s6.e6" /></sentence><sentence text=" Drug-drug interaction via CYP3A inhibition was acknowledged, and weekly labs were ordered to allow for close monitoring of renal function and tacrolimus serum concentrations as recommended by Stribild prescribing information"><entity charOffset="143-153" id="DDI-PubMed.27041642.s7.e0" text="tacrolimus" /></sentence><sentence text=" The patient reported headache, insomnia, stomachache, and decreased urine output within 1 week of starting Stribild and was found to have acute kidney injury (serum creatinine [Scr ]concentration increasing from 1"><entity charOffset="166-176" id="DDI-PubMed.27041642.s8.e0" text="creatinine" /></sentence><sentence text="5-2" /><sentence text="3 mg/dl) and a serum tacrolimus concentration of 111"><entity charOffset="21-31" id="DDI-PubMed.27041642.s10.e0" text="tacrolimus" /></sentence><sentence text="2 ng/ml at 1 week follow-up (goal trough level 4-6 ng/ml)" /><sentence text=" Both tacrolimus and Stribild were withheld"><entity charOffset="6-16" id="DDI-PubMed.27041642.s12.e0" text="tacrolimus" /></sentence><sentence text=" In 15 days, the patient's tacrolimus serum concentration returned to goal"><entity charOffset="27-37" id="DDI-PubMed.27041642.s13.e0" text="tacrolimus" /></sentence><sentence text=" In the interim, he required twice/week clinic visits for laboratory assessments and an emergency department visit for management of hyperkalemia (potassium 6" /><sentence text="5 mEq/L)" /><sentence text=" Triumeq (abacavir, dolutegravir, and lamivudine) was started about 4 weeks later after Scr returned to baseline, and his tacrolimus serum trough concentrations subsequently remained stable"><entity charOffset="1-8" id="DDI-PubMed.27041642.s16.e0" text="Triumeq" /><entity charOffset="10-18" id="DDI-PubMed.27041642.s16.e1" text="abacavir" /><entity charOffset="20-32" id="DDI-PubMed.27041642.s16.e2" text="dolutegravir" /><entity charOffset="38-48" id="DDI-PubMed.27041642.s16.e3" text="lamivudine" /><entity charOffset="122-132" id="DDI-PubMed.27041642.s16.e4" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.27041642.s16.e0" e2="DDI-PubMed.27041642.s16.e0" /><pair ddi="false" e1="DDI-PubMed.27041642.s16.e0" e2="DDI-PubMed.27041642.s16.e1" /><pair ddi="false" e1="DDI-PubMed.27041642.s16.e0" e2="DDI-PubMed.27041642.s16.e2" /><pair ddi="false" e1="DDI-PubMed.27041642.s16.e0" e2="DDI-PubMed.27041642.s16.e3" /><pair ddi="false" e1="DDI-PubMed.27041642.s16.e0" e2="DDI-PubMed.27041642.s16.e4" /><pair ddi="false" e1="DDI-PubMed.27041642.s16.e1" e2="DDI-PubMed.27041642.s16.e1" /><pair ddi="false" e1="DDI-PubMed.27041642.s16.e1" e2="DDI-PubMed.27041642.s16.e2" /><pair ddi="false" e1="DDI-PubMed.27041642.s16.e1" e2="DDI-PubMed.27041642.s16.e3" /><pair ddi="false" e1="DDI-PubMed.27041642.s16.e1" e2="DDI-PubMed.27041642.s16.e4" /><pair ddi="false" e1="DDI-PubMed.27041642.s16.e2" e2="DDI-PubMed.27041642.s16.e2" /><pair ddi="false" e1="DDI-PubMed.27041642.s16.e2" e2="DDI-PubMed.27041642.s16.e3" /><pair ddi="false" e1="DDI-PubMed.27041642.s16.e2" e2="DDI-PubMed.27041642.s16.e4" /><pair ddi="false" e1="DDI-PubMed.27041642.s16.e3" e2="DDI-PubMed.27041642.s16.e3" /><pair ddi="false" e1="DDI-PubMed.27041642.s16.e3" e2="DDI-PubMed.27041642.s16.e4" /></sentence><sentence text=" To our knowledge, this is the first case report describing the extent, significance, and onset of cobicistat and tacrolimus drug-drug interaction in clinical practice"><entity charOffset="114-124" id="DDI-PubMed.27041642.s17.e0" text="tacrolimus" /></sentence><sentence text=" As more fixed-dose combination products including cobicistat as a pharmacokinetic booster come to market, clinicians should be reminded of its multitude of clinically significant drug-drug interactions" /><sentence text="" /></document>